Physician profile
Lawrence A Strong
NPI 1609918671
$12,600.66
in general payments reported to CMS, 2019-2025
42 companies · $2,881 in 2025
The $2,881 reported for 2025 was more than what 84% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,553 · 2020: $1,101 · 2021: $1,335 · 2022: $2,002 · 2023: $2,025 · 2024: $1,704 · 2025: $2,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,529 · Education: $80.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,529.01 |
| Education | $80.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,884.91 | 2019-2025 | Skyrizi, Rinvoq |
| Ucb, INC. | $1,076.41 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $986.14 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $732.47 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Pfizer INC. | $719.14 | 2019-2025 | |
| Leo Pharma INC. | $712.42 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $711.24 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Dermavant Sciences, INC. | $697.29 | 2022-2024 | Vtama |
| Amgen INC. | $534.07 | 2019-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $511.67 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Novartis Pharmaceuticals Corporation | $421.37 | 2019-2025 | |
| Genzyme Corporation | $415.36 | 2019-2024 | |
| Arcutis Biotherapeutics, INC. | $360.61 | 2023-2025 | Zoryve |
| Incyte Corporation | $338.83 | 2021-2025 | Opzelura |
| Almirall LLC | $326.97 | 2019-2025 | Klisyri |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $264.38 | 2019-2024 | Cabtreo, Jublia, Arazlo |
| Genentech USA, INC. | $222.54 | 2019-2021 | |
| Organon LLC | $185.60 | 2025 | Vtama |
| Merz North America, INC. | $181.88 | 2019 | |
| Vyne Pharmaceuticals INC. | $180.70 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.38 | 2023-2025 | Spevigo |
| Lilly USA, LLC | $162.58 | 2020-2025 | Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $97.32 | 2022-2024 | Sotyktu |
| Biofrontera INC. | $92.06 | 2020-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $75.42 | 2019-2025 | |
| Elekta, INC. | $70.52 | 2025 | Flexitron Hdr |
| Strata Skin Sciences, INC. | $50.80 | 2019-2024 | Xtrac |
| Verrica Pharmaceuticals INC. | $47.40 | 2023-2024 | Ycanth |
| Celgene Corporation | $43.44 | 2019-2024 | Sotyktu |
| Lnhc, INC | $42.72 | 2025 | Zelsuvmi |
| Dermira, INC. | $36.30 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $34.91 | 2025 | Purified Cortrophin Gel |
| Botanix Sb INC | $32.32 | 2025 | Sofdra |
| Epi Health, LLC | $27.11 | 2020 | |
| Organogenesis INC. | $24.82 | 2022 | |
| Hydrofera LLC | $24.46 | 2022 | |
| Taro Pharmaceuticals USA, INC. | $22.45 | 2019 | |
| Acera Surgical, INC. | $17.97 | 2022 | |
| Mylan Pharmaceuticals INC. | $16.05 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $14.72 | 2019 | |
| Prugen, INC. Pharmaceuticals | $13.06 | 2019 | |
| Encore Dermatology INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Strong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.